---
title: "Jiangsu Kanion Pharmaceutical Co., Ltd. (600557.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600557.SH.md"
symbol: "600557.SH"
name: "Jiangsu Kanion Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T11:51:52.621Z"
locales:
  - [en](https://longbridge.com/en/quote/600557.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600557.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600557.SH.md)
---

# Jiangsu Kanion Pharmaceutical Co., Ltd. (600557.SH)

## Company Overview

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It also offers medicines in the fields of anti-infections, orthopedics, gynecology, cardio and cerebrovascular, tonic-class, and others. In addition, the company provides herb extracts and formula granules, as well as OEM/ODM services.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.kanion.com](https://www.kanion.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.44)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 117 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -4.99% |  |
| Net Profit YoY | -11.81% |  |
| P/B Ratio | 1.47 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7225692747.96 |  |
| Revenue | 3252393573.75 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.31% | C |
| Profit Margin | 9.23% | B |
| Gross Margin | 74.97% | A |
| Revenue YoY | -4.99% | D |
| Net Profit YoY | -11.81% | D |
| Total Assets YoY | 0.03% | D |
| Net Assets YoY | 6.30% | B |
| Cash Flow Margin | 199.99% | B |
| OCF YoY | -4.99% | D |
| Turnover | 0.47 | C |
| Gearing Ratio | 26.06% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Kanion Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-4.99%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7225692747.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3252393573.75",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.31%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "9.23%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "74.97%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-4.99%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-11.81%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.03%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.30%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "199.99%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-4.99%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.06%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 24.06 | 60/215 | 30.14 | 28.69 | 26.38 |
| PB | 1.47 | 37/215 | 1.95 | 1.80 | 1.68 |
| PS (TTM) | 2.22 | 44/215 | 2.75 | 2.60 | 2.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.48 |
| Highest Target | 17.31 |
| Lowest Target | 17.31 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600557.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600557.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600557.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600557.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**